Cerenis satisfied with Q4 2016, expects good news from clinic in Q1 2017
January 20, 2017French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
The company focused on creating good cholesterol, or HDL therapies for treating cardiovascular and metabolic diseases has reported cash position of €24.7 million at December 31, 2016.
In the last quarter, the company saw ending of CARAT phase 2 study in post-ACS patienst, as the last patient was dosed with placebo. The results of this study are expected by the end of the Q1 2017. The FDA has also given Cerenis the green light to go on with phase 1 trial of CER-209, aimed to study receptor agonist drug candidate (CER-209) to treat Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).
Cerenis’s Chief Executive Officer (CEO) Dr. Jean-Lousi Dasseux said that 2017 will be a milestone year for Cerenis with the results of the CARAT study, expected in the first quarter.
Active enrollment in the phase 3 TANGO trial continues, as Cerenis has engaged 18 sites worldwide for patients with Familial Primary Hypo-Alphalipoproteinemia (FPHA), a rare but clinically important orphan disease.
